BGC20‐1531, a novel, potent and selective prostanoid EP₄receptor antagonist: a putative new treatment for migraine headache

Abstract

BGC20-1531 is a potent and selective antagonist at EP(4) receptors in vitro and in vivo, with the potential to alleviate the symptoms of migraine that result from cerebral vasodilatation. BGC20-1531 is currently in clinical development for the treatment of migraine headache.